Current status and patent prospective of lipid nanoparticle for mRNA delivery

References

• Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19(12):705–713.
   PubMed Web of Science ®Google Scholar
• Oh S, Kessler JA. Design, assembly, production, and transfection of synthetic modified mRNA. Methods. 2018;133:29–43.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588. DOI:10.1084/jem.20171450
   PubMed Web of Science ®Google Scholar
• Kuntsche J, Horst JC, Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm. 2011;417(1–2):120–137.
   PubMed Web of Science ®Google Scholar
• Park S, Choi YK, Kim S, et al. CHARMM-GUI membrane builder for lipid nanoparticles with ionizable cationic lipids and pegylated lipids. J Chem Inf Model. 2021;61(10):5192–5202.
   PubMedGoogle Scholar
• Lee HY, Mohammed KA, Kaye F, et al. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. Int J Nanomedicine. 2013;8:4481–4494.
   PubMed Web of Science ®Google Scholar
• De Jong S, Chikh G, Sekirov L, et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother. 2007;56(8):1251–1264. DOI:10.1007/s00262-006-0276-x. .
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Gupta M, Kim J, et al. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2–12.
   PubMedGoogle Scholar
• Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.
   PubMed Web of Science ®Google Scholar
• Blakney AK, McKay PF, Yus BI, et al. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26(9):363–372. DOI:10.1038/s41434-019-0095-2.
   PubMed Web of Science ®Google Scholar
• Lou G, Anderluzzi G, Schmidt ST, et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: the impact of cationic lipid selection. J Control Release. 2020;325:370–379.
   PubMedGoogle Scholar
• The U.S. Food and Drug Administration. No Title [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
   Google Scholar
• The U.S. Food and Drug Administration. No Title [Internet]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.
   Google Scholar
• Ciaramella G. Influenza vaccine. US10925958B2, 2021.
   Google Scholar
• Ciaramella G. Betacoronavirus mRNA vaccine. US10933127B2, 2021.
   Google Scholar
• Ciaramella G. Chikungunya virus RNA vaccines. US11235052B2, 2022.
   Google Scholar
• Ciaramella G. Infectious disease vaccines. US11007260B2, 2021.
   Google Scholar
• De Fougerolles A. Dlin-Kc2-Dma lipid nanoparticle delivery of modified polynucleotides. US8754062B2, 2014.
   Google Scholar
• Derosa F. Ice-based lipid nanoparticle formulation for delivery of mRNA. US10471153B2, 2019.
   Google Scholar
• Packer M. Lipid nanoparticle compositions and methods of formulating the same. US11524023B2, 2022.
   Google Scholar
• Payne J. Ionizable cationic lipid for RNA delivery. US10961188B2, 2021.
   Google Scholar
• Angel M. Cationic lipids and transfection methods. US11242311B2, 2022.
   Google Scholar
• Payne J. Ionizable cationic lipid for RNA delivery. US10980895B2, 2021.
   Google Scholar
• Derosa F. Biodegradable lipids for delivery of nucleic acids. US10286082B2, 2019.
   Google Scholar
• Ansell S. Lipids and lipid nanoparticle formulations for delivery of nucleic acids. US9738593B2. 2017
   Google Scholar
• Brito L. Lipids and lipid compositions for the delivery of active agents. US11420933B2, 2022.
   Google Scholar
• Smith A. Modified guide RNAs. US11479767B2, 2022.
   Google Scholar
• Moore M. Modified messenger RNA comprising functional RNA elements. US11485972B2, 2022.
   Google Scholar
• Derosa F. Ribonucleic acids with 4′-thio-modified nucleotides and related methods. US10822368B2, 2020.
   Google Scholar
• Chakraborty T. Modified polynucleotides encoding septin-4. US9149506B2, 2015.
   Google Scholar
• Chakraborty T. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1. US10822368B2, 2015.
   Google Scholar
• Frederick J. Combinations of mRnas encoding immune modulating polypeptides and uses thereof. US10172808B2, 2019.
   Google Scholar
• Frederick J. MRNA combination therapy for the treatment of cancer. US10335486B2, 2019.
   Google Scholar
• Frederick J. Combinations of mRnas encoding immune modulating polypeptides and uses thereof. US10322091B2, 2019.
   Google Scholar
• Guild BC. Lipid nanoparticle compositions and methods for mRNA delivery. US11338044B2, 2022.
   Google Scholar
• Guild BC. Lipid nanoparticle compositions and methods for mRNA delivery. US11291734B2, 2022.
   Google Scholar
• Guild BC. Lipid nanoparticle compositions and methods for mRNA delivery. US10350303B1, 2019.
   Google Scholar
• Ciaramella G. Betacoronavirus mRNA vaccine. US10702600B1, 2020.
   Google Scholar
• Rauch S. Coronavirus vaccine. US11241493B2, 2022.
   Google Scholar
• Zhang HL, Li Y. Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis. Pharm Pat Anal. 2021;10(2):73–82. DOI:10.4155/ppa-2021-0004.
   PubMedGoogle Scholar
• Zhang H-L, Y-X L, Zhou A-F, et al. New frontier in antiviral drugs for disorders of the respiratory system. Recent Adv Anti-Infective Drug Discov. 2022;17(1):2–12. DOI:10.2174/1574891X16666220416164740.
   PubMedGoogle Scholar
• Zhang H-L, Li Y. Recent trend for EGFR-Based and ALK-Based targets: a patent analysis. Recent Pat Anticancer Drug Discov. 2021;16(3):298–311.
   PubMed Web of Science ®Google Scholar
• Zhang H-L, Li Y. The patent landscape of BRAF target and KRAS target [Internet]. Recent Pat Anticancer Drug Discov. 2023;18(4):495–505. Available from: http://www.eurekaselect.com/article/128068
   PubMedGoogle Scholar